JUBLPHARMA

Jubilant Pharmova Financial Results

₹973.40-1.60%
Market cap
₹15,417 crore
P/E
43.8
P/B
2.17
ROE
6.0%
Dividend yield
0.51%

For the year ended Mar 2020, Jubilant Pharmova reported revenue of ₹9,154 crore and net profit of ₹898 crore, against ₹2,710 crore and ₹214 crore a year earlier.

Jubilant Pharmova annual profit and loss

Financial years, newest first. TTM = trailing twelve months.

Jubilant Pharmova annual profit and loss (₹ crore)
ItemMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue9,1542,7106,0596,2196,6457,1928,2258,567
Expenses7,2072,2824,9745,4355,7406,0176,9657,349
Operating profit1,9474271,0857849051,1751,2601,218
Operating margin %21%16%18%13%14%16%15%14%
Other income134882-34-96395-44
Interest287102145169256221201207
Depreciation462100382554382369440470
Profit before tax1,21127364028170981614546
Tax %26%21%34%333%57%15%35%36%
Net profit898214413-6573836398351
EPS (₹)56.4713.4826.02-3.834.8752.9925.1622.23
Dividend payout %————————

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Jubilant Pharmova financial results — frequently asked questions

What is Jubilant Pharmova's annual revenue and net profit?

For the financial year ended Mar 2020, Jubilant Pharmova's revenue was ₹9,154 crore and net profit ₹898 crore; net profit rose 319.63% from ₹214 crore in Mar 2021.

How fast has Jubilant Pharmova grown over three years?

From Mar 2023 to Mar 2020, Jubilant Pharmova's revenue grew at a compound annual rate of 13.8%. Past growth does not indicate future results.

What is the EPS of Jubilant Pharmova?

Annual EPS for Mar 2020 was ₹56.47.

Are these figures consolidated or standalone?

They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.

Same Data For Peers

Trade Jubilant Pharmova With ATS

Track JUBLPHARMA live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.